{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T10:38:30Z","timestamp":1794134310451,"version":"4.8.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,4]],"date-time":"2023-03-04T00:00:00Z","timestamp":1677888000000},"content-version":"am","delay-in-days":276,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004963","name":"Seventh Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004963","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006484","name":"Vifor Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006484","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013642","name":"Japan Heart Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013642","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020013","name":"NIHR Leicester Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["EudraCT 2010- 020808-29"],"award-info":[{"award-number":["EudraCT 2010- 020808-29"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["FP7-242209-BIOSTAT-CHF"],"award-info":[{"award-number":["FP7-242209-BIOSTAT-CHF"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004374","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001316","name":"Abbott Laboratories","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.ahj.2022.03.002","type":"journal-article","created":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T20:40:25Z","timestamp":1646858425000},"page":"108-119","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Surrogate markers of gut dysfunction are related to heart failure severity and outcome\u2013from the BIOSTAT-CHF consortium"],"prefix":"10.1016","volume":"248","author":[{"given":"Muhammad Zubair","family":"Israr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Salzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriaan A","family":"Voors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John G","family":"Cleland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan D","family":"Anker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Metra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk J","family":"van Veldhuisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chim C","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilesh J","family":"Samani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leong L","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2022.03.002_bib0001","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/2047487320960288","article-title":"Role of comorbidities in heart failure prognosis Part I: anaemia, iron deficiency, diabetes, atrial fibrillation","volume":"27","author":"Paolillo","year":"2020","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.ahj.2022.03.002_bib0002","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/j.jacc.2007.07.016","article-title":"Altered intestinal function in patients with chronic heart failure","volume":"50","author":"Sandek","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2022.03.002_bib0003","first-page":"220","article-title":"Pathogenic gut flora in patients with chronic heart failure","volume":"4","author":"Pasini","year":"2016","journal-title":"JACC"},{"key":"10.1016\/j.ahj.2022.03.002_bib0004","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1093\/eurheartj\/ehi389","article-title":"The importance of the gastrointestinal system in the pathogenesis of heart failure","volume":"26","author":"Krack","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2022.03.002_bib0005","doi-asserted-by":"crossref","unstructured":"Herrema H, Nieuwdorp M, Groen AK Microbiome and cardiovascular disease. 2020.","DOI":"10.1007\/164_2020_356"},{"key":"10.1016\/j.ahj.2022.03.002_bib0006","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11897-016-0285-9","article-title":"Exploring the microbiome in heart failure","volume":"13","author":"Kitai","year":"2016","journal-title":"Curr Heart Fail Rep"},{"key":"10.1016\/j.ahj.2022.03.002_bib0007","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1161\/CIRCRESAHA.117.309715","article-title":"Gut microbiota in cardiovascular health and disease","volume":"120","author":"Tang","year":"2017","journal-title":"Circ Res"},{"key":"10.1016\/j.ahj.2022.03.002_bib0008","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1136\/heartjnl-2015-308826","article-title":"Trimethylamine N-oxide and prognosis in acute heart failure","volume":"102","author":"Suzuki","year":"2016","journal-title":"Heart"},{"key":"10.1016\/j.ahj.2022.03.002_bib0009","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1002\/ehf2.13290","article-title":"Trimethylamine N-oxide and outcomes in patients hospitalized with acute heart failure and preserved ejection fraction","volume":"8","author":"Kinugasa","year":"2021","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.ahj.2022.03.002_bib0010","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1016\/j.jacc.2014.02.617","article-title":"Prognostic value of elevated levels of intestinal microbe-generated metabolite trimethylamine-N-oxide in patients with heart failure: refining the gut hypothesis","volume":"64","author":"Tang","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2022.03.002_bib0011","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1002\/ejhf.1338","article-title":"Association with outcomes and response to treatment of trimethylamine N-oxide in heart failure: results from BIOSTAT-CHF","volume":"21","author":"Suzuki","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ahj.2022.03.002_bib0012","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1177\/2047487319870355","article-title":"Combined use of trimethylamine N-oxide with BNP for risk stratification in heart failure with preserved ejection fraction: findings from the DIAMONDHFpEF study","volume":"27","author":"Salzano","year":"2020","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.ahj.2022.03.002_bib0013","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.hfc.2019.08.001","article-title":"The gut axis involvement in heart failure: focus on trimethylamine N-oxide","volume":"16","author":"Salzano","year":"2020","journal-title":"Heart Fail Clin"},{"key":"10.1016\/j.ahj.2022.03.002_bib0014","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1177\/2047487319831372","article-title":"Impact of acute choline loading on circulating trimethylamine N-oxide levels","volume":"26","author":"Cassambai","year":"2019","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.ahj.2022.03.002_bib0015","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.cardfail.2015.09.017","article-title":"Intersections between microbiome and heart failure: revisiting the gut hypothesis","volume":"21","author":"Nagatomo","year":"2015","journal-title":"J Card Fail"},{"key":"10.1016\/j.ahj.2022.03.002_bib0016","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ahj.2021.02.017","article-title":"Targeting the gut microbiome in coronary artery disease","volume":"236","author":"Suzuki","year":"2021","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2022.03.002_bib0017","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.3748\/wjg.v20.i12.3223","article-title":"Trefoil factors in inflammatory bowel disease","volume":"20","author":"Aamann","year":"2014","journal-title":"World J Gasteroenterol"},{"key":"10.1016\/j.ahj.2022.03.002_bib0018","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1007\/s00018-008-8646-5","article-title":"The trefoil factor family\u2013small peptides with multiple functionalities","volume":"66","author":"Kjellev","year":"2009","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.ahj.2022.03.002_bib0019","doi-asserted-by":"crossref","DOI":"10.1161\/circ.132.suppl_3.16877","article-title":"High serum levels of trefoil factor 3 are associated with an increased risk for cardiovascular events","volume":"132","author":"Obendorf","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2022.03.002_bib0020","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/ejhf.531","article-title":"A systems biology study to tailored treatment in chronic heart failure: rationale, design, and baseline characteristics of BIOSTAT-CHF","volume":"18","author":"Voors","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ahj.2022.03.002_bib0021","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ahj.2021.01.006","article-title":"Association of gut-related metabolites with outcome in acute heart failure","volume":"234","author":"Israr","year":"2021","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2022.03.002_bib0022","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.jacc.2017.11.041","article-title":"Biomarker-guided versus guideline-based treatment of patients with heart failure: results from BIOSTAT-CHF","volume":"71","author":"Ouwerkerk","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2022.03.002_bib0023","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1002\/ejhf.1550","article-title":"Geographical location affects the levels and association of trimethylamine N-oxide with heart failure mortality in BIOSTAT-CHF: a post-hoc analysis","volume":"21","author":"Yazaki","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ahj.2022.03.002_bib0024","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1002\/ejhf.1951","article-title":"Implications of serial measurements of natriuretic peptides in heart failure: insights from BIOSTAT-CHF","volume":"22","author":"Israr","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ahj.2022.03.002_bib0025","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1093\/eurheartj\/ehx026","article-title":"Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study","volume":"38","author":"Ouwerkerk","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2022.03.002_bib0026","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1161\/ATVBAHA.120.314941","article-title":"Gut feeling: the role of gut microbiota in immunomodulation of ischemia-reperfusion injury","volume":"40","author":"Israr","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ahj.2022.03.002_bib0027","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.jacc.2014.06.1179","article-title":"Intestinal blood flow in patients with chronic heart failure: a link with bacterial growth, gastrointestinal symptoms, and cachexia","volume":"64","author":"Sandek","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2022.03.002_bib0028","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1016\/j.ijcard.2012.04.150","article-title":"Disturbed carnitine regulation in chronic heart failure\u2013increased plasma levels of palmitoyl-carnitine are associated with poor prognosis","volume":"167","author":"Ueland","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ahj.2022.03.002_bib0029","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/iub.323","article-title":"Enzymology of the carnitine biosynthesis pathway","volume":"62","author":"Strijbis","year":"2010","journal-title":"IUBMB life"},{"key":"10.1016\/j.ahj.2022.03.002_bib0030","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.hfc.2019.08.006","article-title":"Cardiac cachexia revisited: the role of wasting in heart Failure","volume":"16","author":"Valentova","year":"2020","journal-title":"Heart Fail Clin"},{"key":"10.1016\/j.ahj.2022.03.002_bib0031","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s10741-012-9340-0","article-title":"Mitochondrial dysfunction in heart failure","volume":"18","author":"Rosca","year":"2013","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.ahj.2022.03.002_bib0032","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1002\/jcsm.12483","article-title":"Sarcopenia: a time for action. An SCWD position paper","volume":"10","author":"Bauer","year":"2019","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.ahj.2022.03.002_bib0033","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nrcardio.2016.203","article-title":"Expert consensus document: Mitochondrial function as a therapeutic target in heart failure","volume":"14","author":"Brown","year":"2017","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.ahj.2022.03.002_bib0034","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/6274854","article-title":"Efficacy and safety of l-carnitine treatment for chronic heart failure: a meta-analysis of randomized controlled trials","volume":"2017","author":"Song","year":"2017","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.ahj.2022.03.002_bib0035","first-page":"815","article-title":"L-carnitine improvement of cardiac function is associated with a stimulation in glucose but not fatty acid metabolism in carnitine-deficient hearts","volume":"30","author":"Broderick","year":"1995","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.ahj.2022.03.002_bib0036","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1007\/s00394-013-0511-0","article-title":"Mechanisms underlying the anti-wasting effect of L-carnitine supplementation under pathologic conditions: evidence from experimental and clinical studies","volume":"52","author":"Ringseis","year":"2013","journal-title":"Eur J Nutr"},{"key":"10.1016\/j.ahj.2022.03.002_bib0037","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-230X-14-74","article-title":"Serum trefoil factor 3 is a promising non-invasive biomarker for gastric cancer screening: a monocentric cohort study in China","volume":"14","author":"Huang","year":"2014","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.ahj.2022.03.002_bib0038","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1515\/med-2015-0020","article-title":"Trefoil factor 3 as a marker of intestinal cell damage during sepsis","volume":"10","author":"\u017durek","year":"2015","journal-title":"Open Med"},{"key":"10.1016\/j.ahj.2022.03.002_bib0039","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ijcard.2018.08.001","article-title":"Utility of temporal profiles of new cardio-renal and pulmonary candidate biomarkers in chronic heart failure","volume":"276","author":"Brankovic","year":"2019","journal-title":"Int J Cardiol"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870322000503?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870322000503?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T06:08:50Z","timestamp":1757570930000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870322000503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":39,"alternative-id":["S0002870322000503"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2022.03.002","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Surrogate markers of gut dysfunction are related to heart failure severity and outcome\u2013from the BIOSTAT-CHF consortium","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2022.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}